BTIG has downgraded Zimmer Biomet Holdings to Neutral from Buy and removed its $112 price target, citing what the brokerage described as weak growth momentum and a lack of near-term catalysts that could materially lift the stock.
The firm said it does not anticipate meaningful share gains over the coming quarters despite management efforts to improve both growth and profitability. BTIG emphasized that Zimmer Biomet's organic revenue expansion has decelerated over the past eight quarters and that management guidance points to continued low single-digit growth - roughly 1% to 3% - in 2026.
BTIG observed that this slowdown appears to be priced into the stock already. The company currently trades at about 10.5x forward earnings, a multiple the broker noted is below that of peers in the sector.
New product introductions have not provided a clear offset to slowing top-line momentum, BTIG said. Zimmer Biomet launched 22 products in 2025 and has plans for eight additional products in 2026, but the brokerage characterized market reception as average and indicated the pipeline has not yet translated into stronger growth.
The firm also pointed to weaker-than-expected results from Paragon 28, an acquisition completed in 2025. BTIG said the acquisition's performance fell short of expectations and has resulted in reduced contribution projections for 2026.
Operational change is another source of uncertainty. Zimmer Biomet is moving its U.S. salesforce to a direct selling model, a transition that BTIG noted will continue through 2027. While the broker acknowledged the change could support improved growth over the longer term, it warned the shift could cause near-term disruption to operations and results.
On the technology front, investments such as autonomous robotics were described as unlikely to meaningfully influence the company's valuation until commercialization. BTIG placed commercialization timing around late 2027 or early 2028, indicating the potential value from these investments remains a longer-term consideration.
Summing up, BTIG concluded that the combination of decelerating growth, limited product-driven upside and execution risks is likely to cap Zimmer Biomet's valuation and restrict share performance, even at the company's currently lower multiples.
Key points
- BTIG downgraded Zimmer Biomet to Neutral from Buy and removed its $112 price target.
- Organic revenue growth has slowed over eight quarters and is forecast by management to be 1% to 3% in 2026; the stock trades at about 10.5x forward earnings, below peers.
- Recent product launches in 2025 (22 products) and planned 2026 additions (8 products) have seen only average market reception; Paragon 28, acquired in 2025, is contributing less than expected for 2026.
Risks and uncertainties
- Execution risk from the U.S. salesforce transition to a direct model, which could cause short-term disruption through 2027 - affecting the medical devices and healthcare equipment sector.
- Product adoption risk, as recent launches have not noticeably accelerated growth - a factor that could limit near-term stock performance in healthcare and medtech equities.
- Timing risk around technology investments such as autonomous robotics, with commercialization expected around late 2027 or early 2028 and unlikely to affect valuation until then.